In this study, we investigated the molecular alterations in combinatory treatment of isoform PI3kinase inhibitors targeting PI3K/Akt/mTOR pathway with Raf/MEK/ERK signaling inhibitor Sorafenib either on PTEN adequate (Huh7) or deficient (Mahlavu) HCC cells (Fig. 1). Here, MAP2K7 is linked to hepatocellular carcinoma.